نتائج البحث - "Claudio Dansky Ullmann"

1

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

المساهمون: O'Connor, Owen A, Özcan, Muhit, Jacobsen, Eric D, Roncero, Josep M, Trotman, Judith, Demeter, Judit, Masszi, Tamá, Pereira, Juliana, Ramchandren, Radhakrishnan, Beaven, Anne, Caballero, Dolore, Horwitz, Steven M, Lennard, Anne, Turgut, Mehmet, Hamerschlak, Nelson, d'Amore, Francesco A, Foss, Francine, Kim, Won-Seog, Leonard, John P, Zinzani, Pier Luigi, Chiattone, Carlos S, Hsi, Eric D, Trümper, Lorenz, Liu, Hua, Sheldon-Waniga, Emily, Ullmann, Claudio Dansky, Venkatakrishnan, Karthik, Leonard, E Jane, Shustov, Andrei R, Lumiere Study Investigators, OMÜ

المصدر: Journal of Clinical Oncology
O'Connor, O A, Özcan, M, Jacobsen, E D, Roncero, J M, Trotman, J, Demeter, J, Masszi, T, Pereira, J, Ramchandren, R, Beaven, A, Caballero, D, Horwitz, S M, Lennard, A, Turgut, M, Hamerschlak, N, d'Amore, F A, Foss, F, Kim, W-S, Leonard, J P, Zinzani, P L, Chiattone, C S, Hsi, E D, Trümper, L, Liu, H, Sheldon-Waniga, E, Ullmann, C D, Venkatakrishnan, K, Leonard, E J, Shustov, A R & Lumiere Study Investigators 2019, ' Randomized ohase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-Cell lymphoma ', Journal of Clinical Oncology, vol. 37, no. 8, pp. 613-623 . https://doi.org/10.1200/JCO.18.00899Test

مصطلحات موضوعية: Male, Oncology, PHARMACOKINETICS, Cancer Research, Time Factors, KINASE INHIBITOR ALISERTIB, chemistry.chemical_compound, 0302 clinical medicine, AURORA KINASE, Recurrence, Single agent, Aurora Kinase A, Aged, 80 and over, Refractory Peripheral T-cell Lymphoma, 0303 health sciences, MLN8237, ORIGINAL REPORTS, Azepines, Middle Aged, APOPTOSIS, 3. Good health, 030220 oncology & carcinogenesis, Early Termination of Clinical Trials, Disease Progression, AUTOPHAGY, Female, EPITHELIAL OVARIAN, Adult, medicine.medical_specialty, Aurora A kinase, Antineoplastic Agents, Peripheral T-Cell Lymphoma, Alisertib, Disease-Free Survival, SIGNALING PATHWAYS, Young Adult, 03 medical and health sciences, Internal medicine, Hematologic Malignancy, medicine, BREAST-CANCER, Humans, In patient, Protein Kinase Inhibitors, Aged, 030304 developmental biology, MESENCHYMAL TRANSITION, business.industry, Lymphoma, T-Cell, Peripheral, Pyrimidines, chemistry, Drug Resistance, Neoplasm, Alisertib, business

وصف الملف: STAMPA; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798208f6ac14caadff6bb3de4243f18fTest
https://doi.org/10.1200/jco.18.00899Test

2

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

المؤلفون: Sandeepraj Pusalkar, Xiaofei Zhou, Yuexian Li, Shawn Searle, Claudio Dansky Ullmann, Swapan Chowdhury, Karthik Venkatakrishnan

المصدر: Investigational New Drugs. 37:666-673

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1366b260b3242676acbfbd3bf604ec4cTest
https://doi.org/10.1007/s10637-018-0693-7Test

3

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

المصدر: Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Alisertib, Lung Neoplasms, Paclitaxel, Population, Phases of clinical research, Placebo, Disease-Free Survival, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Refractory, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, medicine, small-cell lung cancer, Humans, education, Retrospective Studies, education.field_of_study, business.industry, Hazard ratio, SCLC, Azepines, Phase II, 030104 developmental biology, Pyrimidines, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Aurora A kinase, Neoplasm Recurrence, Local, business, Biomarkers